Streetbeat News

RBOT

Vicarious Surgical Inc.

https://www.vicarioussurgical.com

Industry

Medical - Devices

Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Open

14.63

Mkt cap

85M

Volume

74K

High

14.63

P/E Ratio

-1.39

52-wk high

19.00

Low

13.60

Div yield

N/A

52-wk low

4.27

Vicarious Surgical Inc. announced the planned retirement of its COO, John Mazzola, effective April 1, 2025. Mazzola will continue in his role until then, after a long career in healthcare manufacturing and supply chain.

Portfolio Pulse from

February 18, 2025 | 9:30 pm

Vicarious Surgical Inc. announced the departure of its CFO, William Kelly, who has been with the company since January 2021. This change in leadership may impact the company's financial strategy and investor confidence.

Portfolio Pulse from

December 06, 2024 | 9:30 pm

Vicarious Surgical Inc. (NYSE:RBOT) held its Q3 2024 earnings call on November 12, 2024. Key participants included Kaitlyn Brosco, Adam Sachs, and Bill Kelly. The call was attended by analysts such as Adam Maeder from Piper Sandler.

Portfolio Pulse from

November 13, 2024 | 3:15 am

The article highlights significant intraday movements in healthcare stocks, with notable gainers including 180 Life Sciences, Korro Bio, and Universe Pharmaceuticals, and losers such as Novavax and Tevogen Bio Holdings.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 4:31 pm

The article highlights significant intraday movements in healthcare stocks, with NewGenIvf Group, Gritstone Bio, and Vicarious Surgical among the top gainers, while Seelos Therapeutics and Mainz Biomed are notable losers.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 4:32 pm

Piper Sandler analyst Adam Maeder maintains a Neutral rating on Vicarious Surgical (NYSE:RBOT) and adjusts the price target to $12 from $30 following a 1-for-30 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 5:44 pm

Vicarious Surgical has reiterated its expected cash burn of approximately $50 million for the fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:29 pm

Vicarious Surgical (NYSE:RBOT) reported a Q2 2024 adjusted EPS of $(2.86), missing the analyst consensus estimate of $(2.77) by 3.25%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:13 pm

Morgan Stanley analyst Patrick Wood maintains an Equal-Weight rating on Vicarious Surgical (NYSE:RBOT) but lowers the price target from $18 to $10.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 4:58 pm

Vicarious Surgical Inc (NASDAQ:RBOT) shares fell by 20% to $0.29 after announcing a 1-for-30 reverse stock split to meet NYSE's minimum price requirement. The split will take effect on June 12, with trading on a split-adjusted basis starting June 13.

Portfolio Pulse from Henry Khederian

June 11, 2024 | 7:40 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.